RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. ONON
6. FFAI
7. BA
8. RTB
9. ACN
10. AAPL

Go back to RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
AbbVie (NYSE: ABBV) Delayed: 263.96 --0 (-0%)
Previous Close $263.96    52 Week High $68.12 
Open $263.96    52 Week Low $50.71 
Day High $263.96    P/E 57.26 
Day Low $263.96    EPS $4.61 
Volume 402